Editorial
doi: 10.1001/jama.2015.10215.
Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia
Affiliations
- PMID: 26393843
- DOI: 10.1001/jama.2015.10215
Item in Clipboard
Editorial
Dextromethorphan and Quinidine for Treating Agitation in Patients With Alzheimer Disease Dementia
JAMA.
2015 Sep.
No abstract available
Comment on
-
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.JAMA. 2015 Sep 22-29;314(12):1242-54. doi: 10.1001/jama.2015.10214. JAMA. 2015. PMID: 26393847 Clinical Trial.
Similar articles
-
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease.JAMA. 2016 Mar 15;315(11):1166. doi: 10.1001/jama.2015.18286. JAMA. 2016. PMID: 26978214 Free PMC article. No abstract available.
-
Dextromethorphan-Quinidine for Agitation in Alzheimer Disease--Reply.JAMA. 2016 Mar 15;315(11):1166-7. doi: 10.1001/jama.2015.18289. JAMA. 2016. PMID: 26978215 No abstract available.
-
Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.JAMA. 2015 Sep 22-29;314(12):1242-54. doi: 10.1001/jama.2015.10214. JAMA. 2015. PMID: 26393847 Clinical Trial.
-
AVP-786 for the treatment of agitation in dementia of the Alzheimer's type.Expert Opin Investig Drugs. 2017 Jan;26(1):121-132. doi: 10.1080/13543784.2017.1267726. Epub 2016 Dec 11. Expert Opin Investig Drugs. 2017. PMID: 27936965 Review.
-
Advancements in the treatment of agitation in Alzheimer's disease.Expert Opin Pharmacother. 2015;16(11):1649-56. doi: 10.1517/14656566.2015.1059422. Expert Opin Pharmacother. 2015. PMID: 26159445 Review.
Cited by
-
Potential beneficial effects of masupirdine (SUVN-502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analyses.Int J Geriatr Psychiatry. 2022 Oct;37(10):10.1002/gps.5813. doi: 10.1002/gps.5813. Int J Geriatr Psychiatry. 2022. PMID: 36168659 Free PMC article.
-
Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial.Neurotherapeutics. 2017 Jul;14(3):762-772. doi: 10.1007/s13311-016-0508-5. Neurotherapeutics. 2017. PMID: 28070747 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
